StreetWatch: A $2.9 Billion Takeover Put a Spotlight on Relentless Hunger. Palatin Technologies Is Developing the Next Generation of the Drug That Seeks to Treat It

* Rare-endocrine buyers have paid roughly $2.9 billion and approximately $10.0 billion for acquisitions in this area over the past four months. * IMCIVREE, the only approved MC4R agonist for acquired hypothalamic obesity and Bardet-Biedl syndrome, generated $71.3 million of global revenue during the second quarter of 2026, including $51.0 million in the United States and representing a 19% sequential quarter increase in global sales. * Palatin Technologies (NASDAQ: PTN) previously advanced the first FDA-approved melanocortin receptor agonist and is now developing two next-generation MC4R-selective candidates, with IND submissions targeted for the fourth quarter of 2026 and the first half of 2027.

New York, New York--(Newsfile Corp. - August 6, 2026) - Capital is flowing into rare obesity and rare endocrine diseases at an unprecedented pace. In April 2026, Neurocrine Biosciences agreed to acquire Soleno Therapeutics for roughly $2.9 billion, centered on the first approved therapy for hyperphagia associated with Prader-Willi syndrome. Three months later, Vertex Pharmaceuticals agreed to acquire Crinetics Pharmaceuticals for approximately $10.0 billion, underscoring continued strategic interest in differentiated rare endocrine assets.